Cargando…

Single‐cell profiling guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma

In this commentary on Wang, Wu, Xia, and colleagues, Clinical Translational Medicine, 2022, we sum up and discuss recent evidence on the regulation and relevance of the transcription factor c‐FOS in diffuse large B cell lymphoma cells that are treated with epigenetic erasers of the histone deacetyla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krämer, Oliver H., Schneider, Günter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126358/ https://www.ncbi.nlm.nih.gov/pubmed/35604882 http://dx.doi.org/10.1002/ctm2.858

Ejemplares similares

Single‐cell profiling‐guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma
por: Wang, Luqiao, et al.
Publicado: (2022)

The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma
por: Dias, Joana N.R., et al.
Publicado: (2018)

Expression of Histone Deacetylases in Diffuse Large B-cell Lymphoma and Its Clinical Significance
por: Lee, Sung Hak, et al.
Publicado: (2014)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas
por: Zhang, Qing, et al.
Publicado: (2019)

A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors
por: Tula-Sanchez, Ana A, et al.
Publicado: (2013)

The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms
por: Cai, Ying, et al.
Publicado: (2013)

Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma
por: Kim, Soo Jin, et al.
Publicado: (2020)

Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
por: Lu, Guang, et al.
Publicado: (2023)

Targeting histone deacetylases in pancreatic ductal adenocarcinoma
por: Schneider, Günter, et al.
Publicado: (2010)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes
por: Kiweler, Nicole, et al.
Publicado: (2020)

The Sensitivity of Diffuse Large B-Cell Lymphoma Cell Lines to Histone Deacetylase Inhibitor-Induced Apoptosis Is Modulated by BCL-2 Family Protein Activity
por: Thompson, Ryan C., et al.
Publicado: (2013)

Paradoxical Regulation of Hypoxia Inducible Factor-1α (HIF-1α) by Histone Deacetylase Inhibitor in Diffuse Large B-Cell Lymphoma
por: Bhalla, Savita, et al.
Publicado: (2013)

Increased histone deacetylase 6 expression serves as a favorable prognostic factor for diffuse large B-cell lymphoma
por: Lin, Xiao-Ji, et al.
Publicado: (2017)

Recalcitrant Subcutaneous Panniculitis-Like T-Cell Lymphoma Responsive to Histone Deacetylase Inhibitor
por: Gleason, Laura, et al.
Publicado: (2022)

Targetable Metabolic Vulnerability in Diffuse Large B-Cell Lymphoma
por: Xiong, Jie, et al.
Publicado: (2018)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Histone deacetylases – a new target for suppression of cartilage degradation?
por: Mort, John S
Publicado: (2005)

Histone deacetylase 11 as a key regulator of metabolism and obesity
por: Bhaskara, Srividya
Publicado: (2018)

c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors
por: Zheng, Zhong, et al.
Publicado: (2014)

Genome-wide identification of alternative splicing associated with histone deacetylase inhibitor in cutaneous T-cell lymphomas
por: Yu, Shirong, et al.
Publicado: (2022)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
por: Sargent, Daniel J., et al.
Publicado: (2017)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Class 1 Histone Deacetylases and Ataxia-Telangiectasia Mutated Kinase Control the Survival of Murine Pancreatic Cancer Cells upon dNTP Depletion
por: Nguyen, Alexandra, et al.
Publicado: (2021)

The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines
por: Cosenza, Maria, et al.
Publicado: (2016)

Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition
por: Winkler, René, et al.
Publicado: (2022)

Histone Deacetylase Inhibitors in Cell Pluripotency, Differentiation, and Reprogramming
por: Kretsovali, Androniki, et al.
Publicado: (2012)

Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells
por: Wawruszak, Anna, et al.
Publicado: (2019)

Implications of Contact Days in the Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma
por: Bojanini, Leyla, et al.
Publicado: (2023)

Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma
por: Dong, Li Hua, et al.
Publicado: (2013)

Statins and Histone Deacetylase Inhibitors Affect Lamin A/C – Histone Deacetylase 2 Interaction in Human Cells
por: Mattioli, Elisabetta, et al.
Publicado: (2019)

Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
por: Freese, Kim, et al.
Publicado: (2019)

Preventing ototoxic hearing loss by inhibiting histone deacetylases
por: Layman, W S, et al.
Publicado: (2015)

NOXA Accentuates Apoptosis Induction by a Novel Histone Deacetylase Inhibitor
por: Ashry, Ramy, et al.
Publicado: (2023)

Histone deacetylase 6 activity is critical for the metastasis of Burkitt’s lymphoma cells
por: Ding, Ning, et al.
Publicado: (2014)

The Histone Deacetylase Inhibitor LBH589 (Panobinostat) Modulates the Crosstalk of Lymphocytes with Hodgkin Lymphoma Cell Lines
por: Klein, Jan M., et al.
Publicado: (2013)

Triplet Therapy with PD-1 Blockade, Histone Deacetylase Inhibitor, and DNA Methyltransferase Inhibitor Achieves Radiological Response in Refractory Double-Expressor Diffuse Large B-cell Lymphoma with 17p Deletion
por: Zheng, Runhui, et al.
Publicado: (2020)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_v16iu5trgjl9m0igttavlmp4q0